Showing results (211-220 of 261) with videos related to
Sort By:
Pageof 27
European Journal of Dermatology : EJD|August 12, 2008
Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinomaLieven Annemans, Karin Caekelbergh, Rik Roelandts, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 4, 2005
Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infectionsStijn I Blot, Pieter Depuydt, Lieven Annemans, et al.International Journal of Stroke : Official Journal of the International Stroke Society|February 7, 2017
Modified Rankin scale as a determinant of direct medical costs after strokeSarah Dewilde, Lieven Annemans, Andre Peeters, et al.Disability and Rehabilitation|October 3, 2018
The relationship between Home-time, quality of life and costs after ischemic stroke: the impact of the need for mobility aids, home and car modifications on Home-timeSarah Dewilde, Lieven Annemans, Andre Peeters, et al.International Journal of Cardiology|May 31, 2020
Creating the BELgian COngenital heart disease database combining administrative and clinical data (BELCODAC): Rationale, design and methodologyFouke Ombelet, Eva Goossens, Ruben Willems, et al.Journal of Medical Economics|January 3, 2012
Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countriesAurea Duran, Erik Spaepen, Mark Lamotte, et al.Trials|November 8, 2013
Spinal cord stimulation for predominant low back pain in failed back surgery syndrome: study protocol for an international multicenter randomized controlled trial (PROMISE study)Philippe Rigoard, Mehul J Desai, Richard B North, et al.Health and Quality of Life Outcomes|February 9, 2019
The combined impact of dependency on caregivers, disability, and coping strategy on quality of life after ischemic strokeSarah Dewilde, Lieven Annemans, Andrew Lloyd, et al.Diabetes Care|July 28, 2004
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal diseaseAndrew J Palmer, Lieven Annemans, Stéphane Roze, et al.NPJ Digital Medicine|August 18, 2023
Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertensionRuben Willems, Lieven Annemans, George Siopis, et al.Pageof 27